The DOI matches its Crossref record.
THE EFFECT OF ALLOXAN DIABETES ON EXPERIMENTAL CHOLESTEROL ATHEROSCLEROSIS IN THE RABBIT
Open accessAbstract
A comparison was made of the effects of cholesterol feeding in normal rabbits and in rabbits rendered persistently diabetic by means of alloxan. In the two groups of animals hypercholesterolemia of comparable degree was induced by the feeding procedure. Nevertheless, the severity of the atherosclerosis of the aorta produced in the diabetic rabbits was much less than in the non-diabetic control animals. Indeed, a large proportion of the diabetic animals presented no atherosclerosis whatever. There was a similar inhibition of the deposit of lipid substances in the liver, spleen, and adrenal glands of the diabetic rabbits. The inhibition of the development of experimental cholesterol atherosclerosis which was associated with the presence of alloxan diabetes was independent of the administration of alloxan per se. It was not dependent on the sex or weight of the animal, nor upon the daily dosage of cholesterol, the form in which it was administered, nor the duration of cholesterol feeding. It was also independent of changes in body weight occurring during the course of our experiments and of the actual degree of hypercholesterolemia induced by the administration of cholesterol. In addition, there was no gross or histological evidence of a morphological basis for the inhibitory effect either in the aorta or in the other organs in which it was observed. Only two factors were observed to be consistently associated with the inhibition of the expected morphological effects of cholesterol feeding, namely, the diabetic state and a degree of visible lipemia considerably greater than that observed in the control animals. The inhibitory effect observed in these experiments would appear to depend upon some as yet undetermined factor or factors implicit in the diabetic state or closely associated with it. The experimental data presented demonstrate clearly that hypercholesterolemia is not the sole factor concerned in the genesis of experimental cholesterol atherosclerosis, but that another factor, or factors, rendered inoperative in our experiments must be essential to the production of the arterial lesions. In view of the inhibitory effect on the development of experimental cholesterol atherosclerosis observed in alloxan-diabetic rabbits, the effect of alloxan diabetes on the retrogression of such arterial lesions was studied in another series of experiments. No effect on retrogression could be demonstrated within periods lasting up to a maximum of 4 months after the cessation of cholesterol feeding. The results of our two series of experiments, considered together, indicate that the process of deposition of lipids in the arterial walls is governed by factors different from those that are operative in the process of removal of lipids after they have been deposited. The inhibition of the development of experimental cholesterol atherosclerosis in alloxan-diabetic rabbits must depend on interference with the process of deposition of lipids and not on a process of removal of lipids as fast as they are deposited. Our experimental results find no direct application to the problem of arterial disease in human diabetes. Nevertheless, the experimental procedures that we have employed provide a new basis for the design of further experiments directed toward the elucidation of the nature of the unknown factors that govern the process of lipid deposition in the walls of arteries.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Nordestgaard, B. G. (2016) · Circulation Research · doi:10.1161/circresaha.115.306249 · Cited by 1,116
DeFronzo, R. A. (2010) · Diabetologia · doi:10.1007/s00125-010-1684-1 · Cited by 879
Diabetic Dyslipidemia: Causes and Consequences
Goldberg, I. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.3.965 · Cited by 643
Animal Models of Atherosclerosis
Getz, G. S., & Reardon, C. A. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.237693 · Cited by 630
Ischemic Heart Disease, Atherosclerosis, and Longevity
GOFMAN, J. W., YOUNG, W., & TANDY, R. (1966) · Circulation · doi:10.1161/01.cir.34.4.679 · Cited by 587
Hyperglycemia Promotes Myelopoiesis and Impairs the Resolution of Atherosclerosis
Nagareddy, P. R., Murphy, A. J., Stirzaker, R. A., Hu, Y., Yu, S., Miller, R. G., Ramkhelawon, B., Distel, E., Westerterp, M., Huang, L.-S., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.001 · Cited by 577
Insulin and Atheroma: 20-Yr Perspective
Stout, R. W. (1990) · Diabetes Care · doi:10.2337/diacare.13.6.631 · Cited by 571
Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
Di Pino, A., & DeFronzo, R. A. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00141 · Cited by 535
George Lyman Duff Memorial Lecture. Atherogenesis in diabetes.
Bierman, E. L. (1992) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.12.6.647 · Cited by 413
Fan, J., Kitajima, S., Watanabe, T., Xu, J., Zhang, J., Liu, E., & Chen, Y. E. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.09.009 · Cited by 333
DeFronzo, R. A., & Abdul-Ghani, M. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.013 · Cited by 317
Diabetes and atherosclerosis: is there a role for hyperglycemia?
Chait, A., & Bornfeldt, K. E. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800059-jlr200 · Cited by 294
Kritchevsky, D., Tepper, S. A., Wright, S., Tso, P., & Czarnecki, S. K. (2000) · Journal of the American College of Nutrition · doi:10.1080/07315724.2000.10718950 · Cited by 272
Lipoproteins in atherosclerosis
Jones, H. B., Gofman, J. W., Lindgren, F. T., Lyon, T. P., Graham, D. M., Strisower, B., & Nichols, A. V. (1951) · The American Journal of Medicine · doi:10.1016/0002-9343(51)90171-4 · Cited by 267
Duff, G. L., & McMillan, G. C. (1951) · The American Journal of Medicine · doi:10.1016/0002-9343(51)90011-3 · Cited by 263
Self-citationZilversmit, D. B. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.1.153 · Cited by 262
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Ferrannini, E., & DeFronzo, R. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv239 · Cited by 258
Insulin resistance and coronary artery disease
Bressler, P., Bailey, S. R., Matsuda, M., & DeFronzo, R. A. (1996) · Diabetologia · doi:10.1007/s001250050581 · Cited by 226
Nordestgaard, B. G., Stender, S., & Kjeldsen, K. (1988) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.8.4.421 · Cited by 137
Cholesterol feeding exacerbates myocardial injury in Zucker diabetic fatty rats
Hoshida, S., Yamashita, N., Otsu, K., Kuzuya, T., & Hori, M. (2000) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2000.278.1.h256 · Cited by 40
Young, S., Veniant, M., Beigneux, A., Bensadoun, A., & Fong, L. (2008) · Current Drug Targets · doi:10.2174/138945008783755629 · Cited by 33
Metadata
- Authors
- Duff, G. L., & McMillan, G. C.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 1949-06-01
- Volume
- 89
- Issue
- 6
- Pages
- 611-630
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W1527497563
- Cited by
- 248
- References
- 0
- FWCI
- 20.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.